Editorials

Who benefits from medical interventions?

The effects of antiplatelet treatment are a case in point. The meta-analysis of randomised controlled trials of such treatments by the Antiplatelet Trialists' Collaboration shows that the risk of dying from a vascular cause varies substantially according to patient group (p 81).² It ranges from 10% over one month for patients with an acute myocardial infarction at entry to the trial, through 9% over two years for those who had survived an acute myocardial infarction, down to only 2% over five years in trials of primary prevention.

With such varying risks of future vascular events it is unsurprising . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

This article has been cited by other articles:

• Authors/Task Force Members, , Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., Gjelsvik, B., Herrmann-Lingen, C., Hoes, A., Humphries, S., Knapton, M., Perk, J., Priori, S. G., Pyorala, K., Reiner, Z., Ruilope, L., Sans-Menendez, S., Scholte op Reimer, W., Weissberg, P., Wood, D., Yarnell, J., Zamorano, J. L., Other experts who contributed to parts of the guid, , Walma, E., Fitzgerald, T., Cooney, M. T., Dudina, A., European Society of Cardiology (ESC) Committee for, , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Funck-Brentano, C., Filippatos, G., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., Document reviewers:, , Hellemans, I., Altiner, A., Bonora, E., Durrington, P. N., Fagard, R., Giampaoli, S., Hemingway, H., Hakansson, J., Kjeldsen, S. E., Larsen, M. L., Mancia, G., Manolis, A. J., Orth-Gomer, K., Pedersen, T., Rayner, M., Ryden, L., Sammut, M., Schneiderman, N., Stalenhoef, A. F., Tokgozoglu, L., Wiklund, O., Zampelas, A. (2007). European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 28: 2375-2414 [Full text]  
• Davey Smith, G., Timpson, N., Lawlor, D. A. (2006). C-Reactive Protein and Cardiovascular Disease Risk: Still an Unknown Quantity?. ANN INTERN MED 145: 70-72 [Full text]  
• Lynch, J., Davey Smith, G., Harper, S., Bainbridge, K. (2006). Explaining the social gradient in coronary heart disease: comparing relative and absolute risk approaches. J. Epidemiol. Community Health 60: 436-441 [Abstract] [Full text]  
• Llewellyn-Thomas, H. A., Paterson, J. M., Carter, J. A., Basinski, A., Myers, M. G., Hardacre, G. D., Dunn, E. V., D'Agostino, R. B., Wolf, P. A., Naylor, C. D. (2002). Primary Prevention Drug Therapy: Can It Meet Patients' Requirements for Reduced Risk?. Med Decis Making 22: 326-339 [Abstract]  
• McAlister, F. A (2002). Commentary: Relative treatment effects are consistent across the spectrum of underlying risks ... usually. Int J Epidemiol 31: 76-77 [Full text]  
• Hart, C L, Hole, D J, Smith, G D. (2001). The relation between questions indicating transient ischaemic attack and stroke in 20 years of follow up in men and women in the Renfrew/Paisley Study. J. Epidemiol. Community Health 55: 653-656 [Abstract] [Full text]  
• Sterne, J. A C, Egger, M., Smith, G. D. (2001). Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ 323: 101-105 [Full text]  
• Weed, D. L (2001). Commentary: A radical future for public health. Int J Epidemiol 30: 440-441 [Full text]  
• Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gotzsche, P. C., Lang, T., for the CONSORT Group, (2001). The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration. ANN INTERN MED 134: 663-694 [Abstract] [Full text]  
• Hart, C. L, Hole, D. J, Gillis, C. R, Smith, G. D., Watt, G. C., Hawthorne, V. M (2001). Social class differences in lung cancer mortality: risk factor explanations using two Scottish cohort studies. Int J Epidemiol 30: 268-274 [Abstract] [Full text]  
• Heller, R. F, Dobson, A. J, Smeeth, L., Ebrahim, S. (2000). Disease impact number and population impact number: population perspectives to measures of risk and benefit Commentary: DINS, PINS, and things---clinical and population perspectives on treatment effects. BMJ 321: 950-953 [Full text]  
• McAlister, F. A., Straus, S. E., Guyatt, G. H., Haynes, R. B., for the Evidence-Based Medicine Working Group, (2000). Users' Guides to the Medical Literature: XX. Integrating Research Evidence With the Care of the Individual Patient. JAMA 283: 2829-2836 [Abstract] [Full text]  
• Stys, T., Lawson, W. E., Smaldone, G. C., Stys, A. (2000). Does Aspirin Attenuate the Beneficial Effects of Angiotensin-Converting Enzyme Inhibition in Heart Failure?. Arch Intern Med 160: 1409-1413 [Abstract] [Full text]  
• Macleod, J., Loudon, R., Darvill, D., Smeeth, L., Heath, I. (1999). Tackling health inequalities in primary care. BMJ 319: 454a-454 [Full text]  
• Guyatt, G. H., Sinclair, J., Cook, D. J., Glasziou, P., for the Evidence-Based Medicine Working Group and, (1999). Users' Guides to the Medical Literature: XVI. How to Use a Treatment Recommendation. JAMA 281: 1836-1843 [Abstract] [Full text]  
• Hart, C., Smith, G. D. (1998). Knowledge of cardiothoracic ratio adds to cardiovascular risk stratification. BMJ 317: 1321-1321 [Full text]  
• Sheldon, T. A, Guyatt, G. H, Haines, A. (1998). Getting research findings into practice: When to act on the evidence. BMJ 317: 139-142 [Full text]  
• Avins, A. L., Browner, W. S. (1998). Improving the Prediction of Coronary Heart Disease to Aid in the Management of High Cholesterol Levels: What a Difference a Decade Makes. JAMA 279: 445-449 [Abstract] [Full text]  
• Smith, G. D., Egger, M., Phillips, A. N (1997). Meta-analysis: Beyond the grand mean?. BMJ 315: 1610-1614 [Full text]  
• Egger, M., Smith, G. D., Schneider, M., Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634 [Abstract] [Full text]  
• Ebrahim, S., Smith, G. D. (1997). Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease. BMJ 314: 1666-1666 [Abstract] [Full text]  
• Hemminki, E. (1995). The future of population strategies in prevention: Drugs for all?. Scand J Public Health 23: 225-226  
• Glasziou, P. P, Irwig, L. M (1995). An evidence based approach to individualising treatment. BMJ 311: 1356-1359 [Full text]